

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## BREXAFEMME® (Ibexafungerp Tablets) Receives 2021 Popular Science Best of What's New Award in the Health Category

Dec 1 2021, 10:37 AM EST

## SCYNEXIS to Host Ibexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

Nov 29 2021, 8:30 AM EST

## SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibexafungerp Tablets) Over Placebo for Vaginal Yeast Infection

Nov 23 2021, 8:30 AM EST

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

## Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681
ikoffler@lifesciadvisors.com

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

### Christine Coyne

Chief Commercial Officer

### Nkechi Azie, M.D., FIDSA

Vice President, Clinical Development and Medical Affairs

### Jim Maffezzoli

Vice President, Marketing and Sales

### Rajeshwar Motheram, Ph.D.

Senior Vice President, Pharmaceutical Development and Supply Chain

### Glen D. Park, PharmD, MSJ

Vice President, Regulatory Affairs & Quality Assurance

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.